At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Vismodegib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults With Recurrent or Refractory Medulloblastoma
In Brief
A Phase 2 clinical trial evaluating Pharmacological Study and Vismodegib for Adult Medulloblastoma. Completed, enrolled 31 participants across 13 sites.
Detailed Summary
This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells and may be an effective treatment for medulloblastoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Medulloblastoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJul 2009
Primary CompletionMay 2013
Study CompletionAug 2015
TodayJul 2026
First PostedJul 15, 2009
Enrollment StartJun 1, 2009
Primary CompletionMay 1, 2013
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 17.0 years ago
Interventions
Pharmacological Studyother
Correlative studies
Vismodegibdrug
Given PO